Search

Your search keyword '"Horváth, B"' showing total 699 results
Start Over Author "Horváth, B"
699 results on '"Horváth, B"'

52. Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus

Author

Brüggen, M.‐C., primary, Le, S.T., additional, Walsh, S., additional, Toussi, A., additional, Prost, N., additional, Ranki, A., additional, Didona, B., additional, Colin, A., additional, Horváth, B., additional, Brezinova, E., additional, Milpied, B., additional, Moss, C., additional, Bodemer, C., additional, Meyersburg, D., additional, Salavastru, C., additional, Tiplica, G.‐S., additional, Howard, E., additional, Bequignon, E., additional, Bouwes Bavinck, J.N., additional, Newman, J., additional, Gueudry, J., additional, Nägeli, M., additional, Zaghbib, K., additional, Pallesen, K., additional, Bygum, A., additional, Joly, P., additional, Wolkenstein, P., additional, Chua, S.‐L., additional, Le Floch, R., additional, Shear, N.H., additional, Chu, C.‐Y., additional, Hama, N., additional, Abe, R., additional, Chung, W.‐H., additional, Shiohara, T., additional, Ardern‐Jones, M., additional, Romanelli, P., additional, Phillips, E.J., additional, Stern, R.S., additional, Cotliar, J., additional, Micheletti, R.G., additional, Brassard, A., additional, Schulz, J.T., additional, Dodiuk‐Gad, R.P., additional, Dominguez, A.R., additional, Paller, A.S., additional, Seminario‐Vidal, L., additional, Mostaghimi, A., additional, Noe, M.H., additional, Worswick, S., additional, Tartar, D., additional, Sheridan, R., additional, Kaffenberger, B.H., additional, Shinkai, K., additional, Maverakis, E., additional, French, L.E., additional, and Ingen‐Housz‐Oro, S., additional

Published
2021
Full Text
View/download PDF

78. Hidradenitis suppurativa/acne inversa:a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Author

Zouboulis, C. C., Bechara, F. G., Dickinson-Blok, J. L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A. B., Kirby, B., Martorell, A., Podda, M., Prens, E. P., Ring, H. C., Tzellos, T., van der Zee, H. H., van Straalen, K. R., Vossen, A. R.J.V., Jemec, G. B.E., Zouboulis, C. C., Bechara, F. G., Dickinson-Blok, J. L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A. B., Kirby, B., Martorell, A., Podda, M., Prens, E. P., Ring, H. C., Tzellos, T., van der Zee, H. H., van Straalen, K. R., Vossen, A. R.J.V., and Jemec, G. B.E.

Abstract

Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains poorly understood and difficult to manage. Clinical practice is variable, and there is a need for international, evidence-based and easily applicable consensus on HS management. We report here the findings of a systematic literature review, which were subsequently used as a basis for the development of international consensus recommendations for the management of patients with HS. A systematic literature review was performed for each of nine clinical questions in HS (defined by an expert steering committee), covering comorbidity assessment, therapy (medical, surgical and combinations) and response to treatment. Included articles underwent data extraction and were graded according to the Oxford Centre for Evidence-based Medicine criteria. Evidence-based recommendations were then drafted, refined and voted upon, using a modified Delphi process. Overall, 5310 articles were screened, 171 articles were analysed, and 65 were used to derive recommendations. These articles included six randomized controlled trials plus cohort studies and case series. The highest level of evidence concerned dosing recommendations for topical clindamycin in mild disease (with systemic tetracyclines for more frequent/widespread lesions) and biologic therapy (especially adalimumab) as second-line agents (following conventional therapy failure). Good-quality evidence was available for the hidradenitis suppurativa clinical response (HiSCR) as a dichotomous outcome measure in inflammatory areas under treatment. Lower-level evidence supported recommendations for topical triclosan and oral zinc in mild-to-moderate HS, systemic clindamycin and rifampicin in moderate HS and intravenous ertapenem in selected patients with more severe disease. Intralesional or systemic steroids may also be considered. Local surgical excision is suggested for mild-to-moderate HS, with wide excision for more extensive disease. Des

Published
2019

88. IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients.

Author

Lamberts, A., Kotnik, N., Diercks, G.F.H., Meijer, J.M., Di Zenzo, G., Pas, H.H., Jonkman, M.F., Gibbs, B.F., Raap, U., and Horváth, B.

Subjects
BULLOUS pemphigoid, AUTOANTIBODIES, OLDER patients, ENZYME-linked immunosorbent assay, MAST cells, BASAL lamina
Abstract

Background: Non‐bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin diseases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoantibodies may be involved in its pathogenesis. IgE‐activated mast cells, basophils and eosinophils may participate in BP by inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not yet been described. Objective: To assess IgE in serum and skin of NBP and BP patients. Methods: We examined total IgE and pemphigoid‐specific IgE in the serum of 68 NBP and 50 BP patients by enzyme‐linked immunosorbent assay (ELISA). Sera of 25 pemphigus patients and 25 elderly patients with pruritus were included as controls. Skin biopsies of 14 NBP and 14 BP patients with the highest IgE titres to NC16A were stained for IgE by immunofluorescence techniques. Results: Total IgE was elevated in 63% of NBP and 60% of BP patients, and in 20% of pemphigus controls, as well as 60% of elderly controls. IgE ELISAs were more frequently positive in BP than in NBP (NC16A 18% vs. 9%, P = 0.139; BP230 34% vs. 22%, P = 0.149). IgE ELISAs for NC16A and BP230 were positive in 8% and 20% of elderly controls, respectively, while all pemphigus controls were negative. Two of 28 biopsies (7%; one NBP, one BP) showed linear IgE along the basement membrane zone, while in most biopsies (71% NBP; 86% BP) IgE was bound to dermal cells. Conclusion: Since IgE was present in the serum and skin of both NBP and BP patients, this supports IgE‐dependent mechanisms common to both diseases, such as pruritus. However, it remains to be elucidated whether IgE contributes to blister formation in BP. Linked Commentary: I. Kortekaas Krohn. J Eur Acad Dermatol Venereol 2021; 35: 781–782. https://doi.org/10.1111/jdv.17164. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

89. Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid.

Author

Rashid, H., Meijer, J.M., Bolling, M.C., and Horváth, B.

Subjects
BULLOUS pemphigoid, MUCOUS membranes, RITUXIMAB, QUALITY of life
Abstract

Complete remission off therapy was achieved by two patients (29%) with BP and five patients (31%) with MMP (Table 1). Overall, eight patients (35%) relapsed after a median time of 56 weeks [two patients with BP (29%) and six patients with MMP (38%)] (Table 1). In particular, the number of patients receiving prednisone decreased from 18 patients (78%) at M0 to 13 patients (57%) at M6. [Extracted from the article]

Published
2022
Full Text
View/download PDF

90. Hidradenitis suppurativa: De derde oorzaak van vulvacarcinoom

Author

Janse, I. C., Diercks, G. F.H., Doff, J. J., Mourits, M. J.E., Horváth, B., Faculteit Medische Wetenschappen/UMCG, Transplantation Immunology Groningen, Damage and Repair in Cancer Development and Cancer Treatment - 1, and Targeted Gynnaecologic Oncology

Abstract

The development of squamous cell carcinoma (SCC) is a severe complication of chronic HS (HS). HS associated SCC can present as a painful, persistent tumour or ulcer without typical HS characteristics such as sinus formation and inflammation. Especially male patients with prolonged HS in extra-axillary areas are at risk for this complication. This case of HS associated vulvar SCC emphasizes that also women can develop this complication. In addition to lichen sclerosus vulvae (via dVIN) and high risk HPV (via uVIN) there is a third disease that can lead to vulvar cancer; chronic HS. The clinician should be vigilant for the development of malignant transformation in cases of severe, chronic HS, and should have a low threshold for biopsy. Staging, therapy and follow-up should be performed by gynecologic oncologists in an academic center.

Published
2017

91. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

Author

Zouboulis, C.C. Tzellos, T. Kyrgidis, A. Jemec, G.B.E. Bechara, F.G. Giamarellos-Bourboulis, E.J. Ingram, J.R. Kanni, T. Karagiannidis, I. Martorell, A. Matusiak, Ł. Pinter, A. Prens, E.P. Presser, D. Schneider-Burrus, S. von Stebut, E. Szepietowski, J.C. van der Zee, H.H. Wilden, S.M. Sabat, R. the European Hidradenitis Suppurativa Foundation Investigator Group Sinclair, R. Vekic, D. de Haes, P. del Marmol, V. Alavi, A. Gulliver, W. Nassif, A. Nikolakis, G. Podda, M. Antoniou, C. Delli, F.S. Dessinioti, C. Patsatsi, A. Trigoni, A.P. Zisimou, C. Bettoli, V. Garcovich, S. Boer, J. Horváth, B. Ingvarsson, G. Puig, L. Hunger, R.E. Emtestam, L. Danby, F.W. Kimball, A.B.

Abstract

Background: A validated tool for the dynamic severity assessment of hidradenitis suppurativa/acne inversa (HS) is lacking. Objectives: To develop and validate a novel dynamic scoring system to assess the severity of HS. Methods: A Delphi voting procedure was conducted among the members of the European Hidradenitis Suppurativa Foundation (EHSF) to achieve consensus towards an initial HS Severity Score System (HS4). Strengths and weaknesses of HS4 were examined by a multicentre prospective study. Multivariate logistic regression, discriminant analysis and receiver operating characteristic curves, as well as examination for correlation (Spearman's rho) and agreement (Cohen's kappa) with existing scores, were engaged to recognize the variables for a new International HS4 (IHS4) that was established by a second Delphi round. Results: Consensus HS4 was based on number of skin lesions, number of skin areas involved and Dermatology Life Quality Index (DLQI), and was evaluated by a sample of 236 patients from 11 centres. Subsequently, a multivariate regression model calculated adjusted odds ratios for several clinical signs. Nodules, abscesses and draining tunnels resulted as the scoring variables. Three candidate scores were presented to the second Delphi round. The resulting IHS4 score is arrived at by the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4–10 signifies moderate and 11 or higher signifies severe disease. Cohen's kappa was fair (κ = 0·32) compared with Hurley classification, and moderate (κ = 0·49) compared with Expert Opinion. Correlation was good (ρ > 0·6) with Hurley classification, Expert Opinion, Physician's Global Assessment and Modified Sartorius score, and moderate for DLQI (ρ = 0·36). Conclusions: The novel IHS4 is a validated tool to dynamically assess HS severity and can be used both in real-life and the clinical trials setting. © 2017 British Association of Dermatologists

Published
2017

92. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Author

Zouboulis, C.C., primary, Bechara, F.G., additional, Dickinson‐Blok, J.L., additional, Gulliver, W., additional, Horváth, B., additional, Hughes, R., additional, Kimball, A.B., additional, Kirby, B., additional, Martorell, A., additional, Podda, M., additional, Prens, E.P., additional, Ring, H.C., additional, Tzellos, T., additional, Zee, H.H., additional, Straalen, K.R., additional, Vossen, A.R.J.V., additional, and Jemec, G.B.E., additional

Published
2018
Full Text
View/download PDF

94. Omecamtiv mecarbil evokes electromechanical alternans in control rat hearts

Author

Kovács, Á., primary, Fülöp, G.Á., additional, Csípő, T., additional, Nagy, L., additional, Bódi, B., additional, Fagyas, M., additional, Lind-Helgadottir, S., additional, Pórszász, R., additional, Horváth, B., additional, Nánási, P., additional, Oláh, A., additional, Radovits, T., additional, Merkely, B., additional, Hamdani, N., additional, Édes, I., additional, Csanádi, Z., additional, Tóth, A., additional, and Papp, Z., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results